Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 bylo xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu xxx rok 2024 - Mezinárodní standard Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx.

X xxxxx zněním Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky x xxxxxxxxx republiky xxxxxxxx listinu o xxxxxxx xxxx Xxxxxxx X Českou xxxxxxxxxx.

Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx dne 18. xxxxxx 2024 x nahradilo Xxxxxxx X pro xxx 2023, platnou xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 a xxxx xxxxxxx xx českého xxxxxx se xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. JUDr. Xxxxxx, Xx.X., LL.M., x. x.

xxxxxx xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Překlad xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx bude xxxxxxxxx XXXX x xxxx xxxxxxxxxx x xxxxxxxxxx a francouzštině. X případě xxxxxxxxxxx xxxxxxxxxxxxx mezi xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx xxxx uvedeny xxxxxxx pojmy xxxxxxxxx x tomto Seznamu xxxxxxxxxx xxxxx a xxxxx.

Xxxxxxxx Při xxxxxxx

Xxxxx XXXX pro xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, xx období Xxx soutěži x xxxxxx obdobím začínajícím xxxxx před půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Sportovec xxxxxxxxx, xx do xxxxx Xxxxxxx x procesu xxxxxx Xxxxxx.

Xxxxxxxx stále

To xxxxxxx, že daná xxxxx xxxx metoda xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, xxx xx xxxxxxxxxx v Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „pro xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Xxxxxxxx xxxxx Specifickými látkami, x výjimkou xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx metodou, xxxxx xxxx v Xxxxxxx xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx metoda.“ Podle xxxxxxxxx x článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx uvedené x článku 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx xxxxxxxx xxxx méně nebezpečné xxx jiné xxxxxxxxx xxxxx nebo xxxxxx. Xxx xxxxx x xxxxx a metody, xxxxx Xxxxxxxxx pravděpodobně xxxx xxxx xxxxxx x jinému účelu xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx jako látky, xxxxx xxxx xxxx xxxxxx označeny x xxxxxx xxxxxx častého xxxxxxxxxx xx xxxxxxxxxxx xxxx rámec xxxxxx. Xxxx Návykové látky xxxx označovány xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, na xxxxxx xx nevztahuje xxxxx x následujících xxxxxx Seznamu x xxxxx xxxx x xxxxxxxx xxxx schválena xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pro xxxxxxx xxxxxxx x xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji xxxx xxxxxxx vývoj xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx stále.

Tato xxxxx xxxxxxxx xxxxx xxxxxxx látek, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxx (xxxx. Xxxxxxxxxxx x Tirasemtiv).

S1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX I MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX STEROIDY (XXX)

Xxx xxxxxxxxx podání, xxxx jiné xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol)		•	formebolon
•	1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)
•	1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on)
•	7-keto-DHEA		•	metylklostebol
•	11ß-metyl-19-nortestosteron		•	metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on)		•	nandrolon (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)		•	prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol a 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S1.2. XXXXXXX ANABOLICKÉ XXXXX

Xxxx xxxx včetně:

Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, selektivní modulátory xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 a XX-11], zeranol x xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY, PŘÍBUZNÉ XXXXX X MIMETIKA

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx jiné včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx na XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, např. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; daprodustat (XXX1278863); XXX2; molidustat (XXX 85-3934); roxadustat (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (XXX-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Xxxxxxxx xxxxxxxxx opravného xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX HORMONY A XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx testosteron x xxxx, xxxx xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (XX),

• luteinizační xxxxxx (LH),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin),

 • xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny x xxxxxx xxxxxxxxxx faktory, xxxx. kortikorelin a xxxxxxxxxxxxx.

X2.2.3 Růstový hormon (XX), xxxx analogy x xxxxxxxxx, xxxx xxxx xxxxxx:

• xxxxxxx xxxxxxxxx xxxxxxx, např. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,

• fragmenty xxxxxxxxx xxxxxxx, např. XXX-9604 x xXX 176–191.

S2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:

• xxxxxx uvolňující xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx a xxxxxxxxxxx,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a xxxxxx xxxxxxxx [např. anamorelin, xxxxxxxxxxxx, ibutamoren (MK-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx a xxxxxxxxxxx],

• xxxxxxx uvolňující XX (XXXX) [xxxx. alexamorelin, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx růstový xxxxxx (XXX)

• růstový xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx faktor xxxxxxxx x krevních xxxxxxxx (PDGF)

• xxxxxxxx-β4 x xxxx deriváty, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx svalech, xxxxxxxx nebo xxxxxx, xxxxxxxxxxxxx, využití energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx typy svalových xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všichni xxxxxxxxxx x neselektivní xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx jsou xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx formoterol: maximálně xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx x xxxx považována xx Xxxxxxxxx xxxxxxxxxxx nález (XXX), pokud Sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx xxx důsledkem xxxxxxxxxxxx xxxxx (inhalační) xx xx xxxx xxxxxxx maximální xxxxx.

X4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX I MIMO XXXXXX)

Xxxxxxxx xxxxx ve xxxxxxx X4.1 a X4.2 jsou Specifické xxxxx.

Xxxxx xxxxxxxx xx xxxx X4.3 x X4.4 xxxx Nespecifické xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx včetně:

•	2-androstenol (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH RECEPTORŮ (XXXXX)]

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. LÁTKY ZABRAŇUJÍCÍ XXXXXXXX RECEPTORU XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx aktivin X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx expresi xxxxxxxxxx
	- xxxxxxx receptory xxxxxxxx (xxxx. XXX-031)			- xxxxxxxx xxxxxx myostatin (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu)
•	protilátky xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. bimagrumab)			- xxxxxxxxxx neutralizující xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX, agonisté peroxizomovými xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) xxxxxxxx xxxxxx (XX1516, GW501516) x xxxxxxxx Rev-erbɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx látky, xxxxxx xxxxx optických xxxxxxx, xxxx. x- x x-, xxxx zakázány.

Mimo xxxx xxxxxx:

•&xxxx; Diuretika, xxxx xxxx.:

xxxxxxxxxxxx; amilorid; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. konivaptan, mozavaptan, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx intravenózně, xxxx.:

xxxxxxx, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

XXXXXXX

• drospirenon; xxxxxxxx; x xxxxxxx oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. dorzolamid, brinzolamid);

• xxxxxxx xxxxxx felypresinu x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx množství látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: u xxxxxxxxxxx, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx xxxx případně Xxx Xxxxxxx xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx lokálního xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx felypresinu x xxxxxxxx anestezii), bude xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) na xxxx xxxxx navíc k xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO SOUTĚŽ)

Všechny xxxxxxxx metody x xxxx xxxxx xxxx Xxxxxxxxxxxx s xxxxxxxx xxxxx x M2.2, xxx xxxx Specifické xxxxxx.

X1. XXXXXXXXXX S XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx xxxx opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx xxxxxxxx x xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx s výjimkou xxxxxxxx xxxxxx xxxx xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, přenosu xxxx xxxxxxx kyslíku.

Mimo xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x modifikované xxxxxxxxxxxxx produkty, xxxx. xxxxxx xxxxxxxx na xxxx hemoglobinu x xxxxxxxxxxxxxxxx hemoglobinové produkty, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x krví nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. CHEMICKÁ A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx xx účelem xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole.

Mimo xxxx xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X BUNĚČNÝ DOPING

Z xxxxxx potencionálního xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx kyselin nebo xxxxxx xxxxxxx, které xxxxx xxxxxx sekvence xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo xxxx xxxxxxxx xxxxxxxxxxx úprav xxxx, umlčování genů x xxxxxxxxxxx přenosů xxxx.

X3.2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Specifické xxxxx x výjimkou xxxxx xxxxxxxxx x X6.X, xxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxx látky x xxxx sekci: xxxxxx x metylendioxymetamfetamin (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a l-, xxxx zakázána.

Stimulancia xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx jiné včetně:

•	2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx x xxxx analogy, xxxx. xxxxxxxx, metedron a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (metylendioxyamfetamin)
•	etylamfetamin		•	norfenefrin		•	tuaminoheptan
•	etilefrin		•	oktodrin (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx kožního, xxxxxxx, očního xxxx xxxxxx použití (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x stimulancia zařazená xx Monitorovacího programu 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx optických xxxxxxx, xxxx. x- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx a xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 KANABINOIDY

ZAKÁZANÉ XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx. Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xxxx.

• x konopí (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• přírodní x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (THC)

• xxxxxxxxxx xxxxxxxxxxx napodobující xxxxxx THC

VÝJIMKY

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx glukokortikoidy xxxx xxxxxxxx, pokud xxxx podávány xxxxxxxxxx xxxxxxxx, perorální [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx xxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx a xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx a xxxxxxxxxxxx) xxxxxx zakázány, xxxxx xx xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx indikací.

P1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Beta-blokátory xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx a xxx xx xx označeno xxxxxxxx (*) i Xxxx soutěž.

• lukostřelba (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx na xxxxxx, akrobatické xxxxx / X-xxxxx x xxxxxxxxx X-xxxxx / xxx air

• automobilový xxxxx (XXX)

• podvodní xxxxxx (XXXX)* x xxxxxxxxxxxx volného xxxxxxxx, xxxx harpunou x xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• xxxxx (WDF)

• xxxx (XXX)

• xxxxxxxx (XXX)

• xxxxxxx (ISSF, XXX)*

* xxxxxxxx xxxx Xxxx soutěž

Mimo xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx č. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx jazyce
 

¹⁾ katin (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx vyšší xxx 5 xxxxxxxxxx x 1 xx.

²⁾ xxxxxxxxxxxxx: zakázaný xxxxx xxx xxxxxxxxxxx v xxxx xxxxx xxx 150 xxxxxxxxxx x 1 ml.

³⁾ xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx než 10 xxxxxxxxxx x 1 xx.

⁴⁾ epinefrin (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, oční, xxxx xxxxxxxx podávání s xxxxxxxxx xxxxxxxxxx.

⁵⁾ bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol x xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx netýká xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu